Exclusive deal : 20% Instant discount on Direct purchases! Don't wait—claim your discount today!
Global Human Recombinant Insulin Market 2020 By Product [Regular (short acting) insulin, NPH (intermediate acting) insulin, Premixed human insulins insulin and others], By Distribution Channel [Hospitals, Retail pharmacies, Online pharmacies and Others]: Global Forecast to 2026 and COVID-19 Impact Outlook
Global Human Recombinant Insulin Market is valued at USD 29.48 Billion in 2019 and expected to reach USD 48.33 Billion by 2026 with the CAGR of 7.33 % over the forecast period.
Scope of the report
This report analyses the global market for Human Recombinant Insulin. The report will enable the user to understand and gain insights into the current and forecast market situation. The market is comprehensively analyzed by geography to give complete information on the global scenario. The qualitative and quantitative data provided in this study can help user understand which market segments, regions are expected to grow at higher rates, factors affecting the market and key opportunity areas. The report also includes competitive landscape of key players in the industry along with emerging trends in the market.
Key Players
Biocon, Bioton S.A., Dongbao Enterprise Group Co Ltd., Eli Lilly and Company, Gan & Lee Pharmaceuticals, Ltd., Julphar Gulf Pharmaceutical Industries, Novo Nordisk A/S, Sanofi S.A., Wanbang Biopharmaceuticals Co Ltd., Zhuhai United Laboratories Co Ltd. and others
Above mentioned companies were scrutinized to assess competitive landscape of global Human Recombinant Insulin market. Report provides company profiles of each player. Each profile include company product portfolio,business overview, company governance, company financials, business strategies, manufacturing locations and production facilities, company sale, recent developments and strategic collaborations & partnerships, new product launch, company segments, application diversification and company strength and weakness analysis.
Review period: (2016-2026)
Historic Period: 2016 to 2019
Forecast Period: 2020 to 2026
Base Year: 2019
Unit: USD Billion
This Human Recombinant Insulin market report provides insights on new trade regulations, import export analysis, industry value chain analysis, market size, consumption, production analysis, capacity analysis, regional and segment market share, product launches, product pipeline analysis, impact of Covid-19 on supply chain, key regions, untapped markets, patent analysis, product approvals, continuous innovations and developments in the market.
Regions
• North America: U.S., Canada and Rest of North America
• Europe: UK, France, Germany, Italy, Spain and Rest of Europe
• Asia Pacific: China, Japan, India, Australia, Southeast Asia and Rest of Asia Pacific
• Latin America: Brazil, Mexico, Argentina and Rest of Latin America
• Middle East and Africa: Gulf Countries, Israel, Africa and Rest of Middle East and Africa
Market Segmentation
• Product
o Regular (short acting) insulin
o NPH (intermediate acting) insulin
o Premixed human insulins insulin
• Distribution Channel
o Hospitals
o Retail pharmacies
o Online pharmacies
o Others
Report Coverage
• An overview of the global Human Recombinant Insulin market
• In depth analysis of market dynamics and major factors such as drivers, restraints, opportunities and trends influencing the global market
• Global Human Recombinant Insulin market revenue data historic and forecast analysis (2016 to 2026)
• Characterization and quantification of the market segments for Human Recombinant Insulin market
• Market share analysis of key market participants and their competitive landscape
Important Questions Answered by Global Human Recombinant Insulin Market Report
• What is the impact of COVID 19 epidemic on the global Human Recombinant Insulin market
• Which is mostly affected region, country
• Which is the current largest and fastest-growing region
• What is the market size and growth rate of the global Human Recombinant Insulin market
• What are current factors affecting the growth of market
• What are Key trends and opportunity areas
• Within Human Recombinant Insulin market, which segments are fastest growing & emerging strongly What are the drivers and restraints for each segment What are vendor competencies by segment
• What are the major strategies adopted by leading market companies
• What are company challenges and essential success factors by marketsegment
• How company offerings and supply chain capabilitiesare shifting to meetemerging market needs
1. Introduction
1.1. Report Description
1.2. Market Segmentation
1.3. Research Methodology
1.4. List of Abbreviations
2. Executive Summary
3. Market Overview
3.1. Market Definition
3.2. Market Scope
3.3. Market Drivers
3.4. Market Restraints
3.5. Market Opportunities and Trends
3.6. Porter’s five force analysis
3.7. SWOT Analysis
3.8. PEST Analysis
3.9. Patent Analysis
3.10. Impact of COVID 19 on Global Human Recombinant Insulin Market
4. Human Recombinant Insulin Market, By Product, Market Size and Forecast 2016 -2026 (USD Billion)
4.1. Global Human Recombinant Insulin Market By Product, 2016 -2026 (USD Billion)
4.1.1. Global Human Recombinant Insulin Market By Regular (short acting) insulin
4.1.2. Global Human Recombinant Insulin Market By NPH (intermediate acting) insulin
4.1.3. Global Human Recombinant Insulin Market By Premixed human insulins insulin
4.2. Global Human Recombinant Insulin Market By Product Share, 2016 -2026 (%)
5. Human Recombinant Insulin Market, By Distribution Channel, Market Size and Forecast 2016 -2026 (USD Billion)
5.1. Global Human Recombinant Insulin Market By Distribution Channel, 2016 -2026 (USD Billion)
5.1.1. Global Human Recombinant Insulin Market By Hospitals
5.1.2. Global Human Recombinant Insulin Market By Retail pharmacies
5.1.3. Global Human Recombinant Insulin Market By Online pharmacies
5.1.4. Global Human Recombinant Insulin Market By Others
5.2. Global Human Recombinant Insulin Market By Distribution Channel Share, 2016 -2026 (%)
6. Human Recombinant Insulin Market, By Region Market Size and Forecast 2016 -2026
6.1. NORTH AMERICA
6.1.1. Key Findings
6.1.2. Impact of COVID 19
6.1.3. Key market trends, growth factors and opportunities
6.1.4. North America Human Recombinant Insulin Market by Country 2016 -2026 (USD Billion)
6.1.5. North America Human Recombinant Insulin Market By Product 2016 -2026 (USD Billion)
6.1.6. North America Human Recombinant Insulin Market By Distribution Channel 2016 -2026 (USD Billion)
6.2. EUROPE
6.2.1. Key Findings
6.2.2. Impact of COVID 19
6.2.3. Key market trends, growth factors and opportunities
6.2.4. Europe Human Recombinant Insulin Market by Country 2016 -2026 (USD Billion)
6.2.5. Europe Human Recombinant Insulin Market By Product 2016 -2026 (USD Billion)
6.2.6. Europe Human Recombinant Insulin Market By Distribution Channel 2016 -2026 (USD Billion)
6.3. ASIA PACIFIC
6.3.1. Key Findings
6.3.2. Impact of COVID 19
6.3.3. Key market trends, growth factors and opportunities
6.3.4. Asia Pacific Human Recombinant Insulin Market by Country 2016 -2026 (USD Billion)
6.3.5. Asia Pacific Human Recombinant Insulin Market By Product 2016 -2026 (USD Billion)
6.3.6. Asia Pacific Human Recombinant Insulin Market By Distribution Channel 2016 -2026 (USD Billion)
6.4. LATIN AMERICA
6.4.1. Key Findings
6.4.2. Impact of COVID 19
6.4.3. Key market trends, growth factors and opportunities
6.4.4. Latin America Human Recombinant Insulin Market by Country 2016 -2026 (USD Billion)
6.4.5. Latin America Human Recombinant Insulin Market By Product 2016 -2026 (USD Billion)
6.4.6. Latin America Human Recombinant Insulin Market By Distribution Channel 2016 -2026 (USD Billion)
6.5. MIDDLE EAST AND AFRICA
6.5.1. Key Findings
6.5.2. Impact of COVID 19
6.5.3. Key market trends, growth factors and opportunities
6.5.4. Middle East and Africa Human Recombinant Insulin Market by Country 2016 -2026 (USD Billion)
6.5.5. Middle East and Africa Human Recombinant Insulin Market By Product 2016 -2026 (USD Billion)
6.5.6. Middle East and Africa Human Recombinant Insulin Market By Distribution Channel 2016 -2026 (USD Billion)
7. Competitive Landscape Analysis
7.1. Global Human Recombinant Insulin Market Company Revenue, (USD Billion), 2016-2019
7.2. Global Human Recombinant Insulin Market Company Share, (%), 2016-2019
8. Company Profiles
8.1. Biocon
8.2. Bioton S.A.
8.3. Dongbao Enterprise Group Co Ltd.
8.4. Eli Lilly and Company
8.5. Gan & Lee Pharmaceuticals, Ltd.
8.6. Julphar Gulf Pharmaceutical Industries
8.7. Novo Nordisk A/S
8.8. Sanofi S.A.
8.9. Wanbang Biopharmaceuticals Co Ltd.
8.10. Zhuhai United Laboratories Co Ltd.
8.11. Others
9. Appendix
10. List of Tables
11. List of Figures
Research Methodology:
Human Recombinant Insulin Market Size Estimation
To estimate market size and trends, we use a combination of top-down and bottom-up methods. This allows us to evaluate the market from various perspectives—by company, region, product type, and end users.
Our estimates are based on actual sales data, excluding any discounts. Segment breakdowns and market shares are calculated using weighted averages based on usage rates and average prices. Regional insights are determined by how widely a product or service is adopted in each area.
Key companies are identified through secondary sources like industry reports and company filings. We then verify revenue estimates and other key data points through primary research, including interviews with industry experts, company executives, and decision-makers.
We take into account all relevant factors that could influence the market and validate our findings with real-world input. Our final insights combine both qualitative and quantitative data to provide a well-rounded view. Please note, these estimates do not account for unexpected changes such as inflation, economic downturns, or policy shifts.
Data Source
Secondary Sources
This study draws on a wide range of secondary sources, including press releases, annual reports, non-profit organizations, industry associations, government agencies, and customs data. We also referred to reputable databases and directories such as Bloomberg, Wind Info, Hoovers, Factiva, Trading Economics, Statista, and others. Additional references include investor presentations, company filings (e.g., SEC), economic data, and documents from regulatory and industry bodies.
These sources were used to gather technical and market-focused insights, identify key players, analyze market segmentation and classification, and track major trends and developments across industries.
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Primary Sources
As part of our primary research, we interviewed a variety of stakeholders from both the supply and demand sides to gather valuable qualitative and quantitative insights.
On the supply side, we spoke with product manufacturers, competitors, industry experts, research institutions, distributors, traders, and raw material suppliers. On the demand side, we engaged with business leaders, marketing and sales heads, technology and innovation directors, supply chain executives, and end users across key organizations.
These conversations helped us better understand market segmentation, pricing, applications, leading players, supply chains, demand trends, industry outlook, and key market dynamics—including risks, opportunities, barriers, and strategic developments.
Key Data Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments(by Application, by Type) |
|
|
| Total Market |
|
|